Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brigham & Women's Hospital
New protease inhibitors offer improved tolerability and safety
June 26th, 2004
New protease inhibitors offer improved tolerability and safety. "Poor tolerability is a major cause of nonadherence and treatment discontinuation with protease inhibitors (PIs). Gastrointestinal (GI) disturbances are often cited as affecting PI tolerability, but other adverse effects, such as those that affect patient appearance or self-perception, can also negatively impact patient acceptance and adherence to or continuation of therapy. Long-term complications-such as lipodystrophy, hyperlipidemia, and insulin resistance-can deter patients from beginning therapy or discourage them from continuing therapy once it is begun," scientists at Brigham & Woman's Hospital...
Source: Law & Health Weekly (2004-06-26)
|
